Turkovac
{{cs1 config|name-list-style=vanc}}
{{Short description|Vaccine against COVID-19}}
{{Use dmy dates|date=November 2023}}
{{Infobox drug
| Verifiedfields =
| verifiedrevid =
| drug_name = Turkovac
| INN =
| type = vaccine
| image =
| alt =
| caption =
| target = SARS-CoV-2
| vaccine_type = inactivated
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| licence_EU =
| licence_US =
| pregnancy_AU =
| pregnancy_category =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_UK =
| legal_US =
| legal_UN =
| legal_NZ =
| legal_status = Full list of Turkovac authorizations
| routes_of_administration = Intramuscular
| ATCvet =
| ATC_prefix =
| ATC_suffix =
| CAS_number = 2695585-27-2
| PubChem =
| DrugBank =
| synonyms = Erucov-Vac
}}
{{COVID-19 pandemic sidebar}}
Turkovac{{cite news | vauthors = Cakmak BN |title=Turkey names home-grown COVID-19 jab Turkovac |url= https://www.aa.com.tr/en/health/turkey-names-home-grown-covid-19-jab-turkovac/2281883 |agency=Anadolu Agency |date=22 June 2021}} (pronunciation: Help:IPA/Turkish) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.
__TOC__
Clinical trials
In November 2020, Turkovac started on phase I trials with 44 participants in Turkey.{{ClinicalTrialsGov|NCT04691947 |Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine Erucov-Vac}}
In February 2021, Turkovac started on phase II trials with 250 participants in Turkey.{{ClinicalTrialsGov|NCT04824391|Efficacy, Immunogenicity and Safety of Inactivated Erucov-Vac Compared With Placebo in COVID-19 }}
In June 2021, Turkovac started on phase III trials with 40,800 participants in Turkey.{{Cite web|title=Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (Turkovac) Versus the CoronaVac Vaccine |url=https://clinicaltrials.gov/ct2/show/NCT04942405 |website=ClinicalTrials.gov |date=28 June 2021 |id=NCT04942405 |access-date=29 June 2021 }} {{As of|2023}} phase III trials continue.{{Cite web |title=ClinicalTrials.gov |url=https://www.clinicaltrials.gov/study/NCT05077176?intr=Turkovac&term=Phase%20III&rank=1 |access-date=2024-01-16 |website=www.clinicaltrials.gov}}
Authorization
On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed.{{Cite news|title=Turkey issues emergency-use authorization for its domestically produced vaccine.|url=https://www.nytimes.com/2021/12/22/world/europe/turkey-issues-emergency-use-authorization-for-its-domestically-produced-vaccine.html|access-date=2021-12-28|newspaper=The New York Times|date=22 December 2021 }} On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.{{Cite news|date=23 December 2021|title=Turkey authorises use of own Turkovac Covid-19 vaccine|work=France 24|url=https://www.france24.com/en/video/20211223-turkey-authorises-use-of-own-turkovac-covid-19-vaccine|access-date=24 December 2021}}
References
{{reflist}}
{{scholia}}
{{Vaccines}}
{{COVID-19 pandemic}}
{{Portal bar | Medicine | Viruses | COVID-19}}
Category:Turkish COVID-19 vaccines
Category:Drugs not assigned an ATC code
Category:Products introduced in 2020
{{COVID19-vaccine-stub}}
{{Vaccine-stub}}